Recruiting

Intrathecal Port

Sponsor:

Alcyone Therapeutics, Inc

Code:

NCT05866419

Conditions

Spinal Muscular Atrophy

Spine Deformity

Scoliosis

Eligibility Criteria

Sex: All

Age: 3+

Healthy Volunteers: Not accepted

Interventions

ThecaFlex DRx System

Study Details

Brief summary:

The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).

All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.

Conditions

Spinal Muscular Atrophy

Spine Deformity

Scoliosis

Study ID

NCT05866419

Start date

Nov 27, 2023

Status verified date

Aug, 2026

Completion date

Jul, 2030

Anticipated

Primary completion date

Apr, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 3+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Subject is 3 years or older
2. Subject is diagnosed with SMA and is a candidate for Spinraza treatment as indicated in country-specific label
3. Subject resistant to lumbar puncture (LP), where resistance is defined as:

1. Subject with respiratory issues or other comorbidities who is at an increased risk for complications due to the need for repeat anesthesia and imaging radiation exposure to safely perform LP; or
2. Subjects for whom the treating physician determines implantation of the ThecaFlex DRx™ System is otherwise in the subject's best interest
4. Subject has been prescribed nusinersen via chronic intrathecal bolus administration in accordance with the country-specific drug labeling
5. Subject, per Investigator discretion, is able to undergo a percutaneous or open surgical procedure for index port and catheter implantation where at least 7 cm of the ThecaFlex DRx system catheter will be placed intrathecally
6. Subject (or subject's legally authorized representative) is willing and able to provide written informed consent; and
7. Subject and parent/caregiver able and willing to complete all clinical investigation procedures, measurements, and visits.

Exclusion Criteria:

1. Subject meets any of the contraindications for use of the ThecaFlex DRx System as outlined in the ThecaFlex DRx System Instructions for Use
2. Presence or history of (< 6 months prior to the procedure): an implanted microinfusion pump, intrathecal catheter, or other intrathecal drug delivery devices/component, or implanted shunt for drainage of cerebrospinal fluid (CSF), or reservoir in the CSF space (note: any ThecaFlex Port and Catheter System must not be placed in the same location as a previous indwelling port and catheter)
3. Subject is pregnant or nursing or plans to become pregnant during the course of the clinical investigation, or is a woman of childbearing potential or a man of reproductive age who is unwilling or unable to practice contraception, as described in Section 14.10.
4. Any condition or event, which in the opinion of the Investigator may adversely affect the safety and effective implantation and use of the ThecaFlex DRx system or confound the clinical investigation, including:

1. Severe structural impediment that may preclude safe implantation of the catheter and port
2. Major medical events (as defined per investigator's discretion) within 60 days prior to screening; or
3. Relevant surgeries (e.g., head and neck, back, etc.) within 60 days prior to screening or planned during the duration of the clinical investigation
4. Space-occupying lesion with mass effect
5. Posterior fossa mass
6. Arnold-Chiari malformation
7. Coagulation abnormalities and/or thrombocytopenia
8. Insufficient or inadequate skin or underlying fat to adequately protect the port or enough surface area to allow the skin to close safely
5. Subject is contraindicated for administration of nusinersen per its approved country-specific labeling
6. History of intrathecal granuloma formation
7. History of bacterial meningitis or aseptic meningitis within 6 months of screening
8. History of tumors or other spinal abnormalities documented by magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with the catheter implantation procedures or CSF circulation
9. History of hydrocephalus
10. Diagnosed degenerative muscular disease other than SMA
11. History of depression, cognitive impairment, or another psycho-behavioral problem that in the opinion of the Investigator may preclude safe participation in the clinical investigation and
12. Serious medical condition that, in the opinion of the investigator, may lead to reduced life expectancy beyond 12 months.
13. Subject is involved in another Investigation Device Exemption Study.
14. Subject has clinically meaningful immunosuppression, in the opinion of the investigator, either from therapy or a comorbid condition, which, in the opinion of the investigator, makes them a poor surgical candidate due to increased risk of infection.

Study Design

Enrollment

90 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: ThecaFlex DRx Port and Catheter System

Subjects who meet all of the inclusion and none of the exclusion would be eligible to receive the ThecaFlex DRx Port and Catheter System.

Interventions

ThecaFlex DRx System

The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.

Primary outcome measure

  • The proportion of subjects with successful Implantation of the ThecaFlex DRx™ Port and Catheter [ Time Frame: 12 Months ]
  • The proportion of subjects with successful Intrathecal Therapy Infusion(s) through 12 months [ Time Frame: 12 Months ]

Central Contacts and Locations

Central contacts

Locations

Barrow Neurological Institute

Recruiting

Phoenix, Arizona, United States, 85013

Contacts

Principal Investigator:

Shafeeq Ladha, MD

Children's Hospital Orange County

Recruiting

Orange, California, United States, 92868

Contacts

Stanford Medical Center

Recruiting

Palo Alto, California, United States, 94301

Contacts

Rady Children's Hospital

Recruiting

San Diego, California, United States, 92037

Contacts

Elizabeth Moreno

e4moreno@health.ucsd.edu

Nemours Children's Hospital, Florida

Recruiting

Orlando, Florida, United States, 32827

Contacts

Lurie Childrens Hospital

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Helen DeVos Children's Hospital

Recruiting

Grand Rapids, Michigan, United States, 49503

Contacts

Columbia University Irving Medical Center/NewYork Presbyterian Hospital

Recruiting

New York, New York, United States, 10032

Contacts

UH Rainbow Babies and Children's Hospital

Recruiting

Cleveland, Ohio, United States, 44106

Contacts

Penn State Milton S. Hershey Medical Center

Recruiting

Hershey, Pennsylvania, United States, 17033

Contacts

Children's Hospital Philadelphia

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Samantha Gogel

Gogels@chop.edu

Texas Children's Hospital

Recruiting

Houston, Texas, United States, 77030

Contacts

University of Virginia

Recruiting

Charlottesville, Virginia, United States, 22903

Contacts

Childrens Hospital of the King's Daughters

Recruiting

Norfolk, Virginia, United States, 23510

Contacts

More Information

Sponsor

Alcyone Therapeutics, Inc

Last update posted

Aug 19, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Alcyone Therapeutics, Inc on 2026-08-19.